Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating fibrotic cancers

a fibrotic cancer and treatment method technology, applied in the field of fibrotic cancer treatment methods, can solve the problems of poor clinical outcome, inadequate organ function, difficult treatment of fibrotic cancer, etc., and achieve the effect of improving efficacy and/or responsiveness to that agent, decreasing effectiveness, and improving efficacy and/or responsiveness

Active Publication Date: 2016-08-18
PROMEDIOR
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method of treating cancer using a combination of an SAP polypeptide (SAP agonist) and an anti-cancer therapeutic. The SAP agonist can be a fusion protein that includes an SAP domain and one or more heterologous domains to enhance stability, half-life, and uptake of the therapeutic. The anti-cancer therapeutic can be a chemotherapy agent, antibody-based agent, or a tyrosine kinase inhibitor. The method can improve the safety and efficacy of the therapeutic and lead to increased clinical benefit. The patent also describes the use of an SAP agonist in combination with other anti-cancer therapeutics for patients who are resistant or have plateaued response to the therapeutic alone. Overall, the patent provides a novel approach for treating cancer that combines the benefits of multiple therapeutics to improve efficacy and safety.

Problems solved by technology

Such fibrotic cancers are difficult to treat because chemotherapeutic agents often cannot penetrate the dense fibrotic stroma surrounding the cancer cells.
In other cancers, such as myelofibrosis, replacement of healthy organ tissue by fibrosis results in inadequate organ function, which contributes to the symptoms of the cancer.
Despite aggressive treatment regimens, resistance of fibrotic cancers to chemotherapeutic agents has resulted in poor clinical outcome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating fibrotic cancers
  • Methods for treating fibrotic cancers
  • Methods for treating fibrotic cancers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of Myelofibrosis with α2,3-Sialic Acid-Containing Sap Alone and in Combination with Ruxolitinib: Stage 1 Results at 12 Weeks

[0203]Recombinant human SAP, in this case the recombinant human SAP known as PRM-151, was administered to myelofibrosis (MF) patients, alone and in combination with ruxolitinib (RUX), to evaluate safety and efficacy in treating bone marrow fibrosis (BMF). Patients with Intermediate-1, Intermediate-2, or high risk MF with grade ≧2 BMF, either not receiving therapy or on a stable dose of RUX, were eligible for this study.

[0204]Twenty-seven patients were assigned to one of four cohorts based on administration of PRM-151 as a monotherapy or as part of a combination therapy. Cohort 1: i) patients who received no treatment for MF in at least two weeks, ii) were administered an initial loading dose of SAP at 10 mg / kg by intravenous infusion (˜1 hour infusion) on days 1, 3, and 5, and iii) thereafter were administered a dose of SAP every four weeks at 10 mg / k...

example 2

Treatment of Myelofibrosis with Prm-151 Alone and in Combination with Ruxolitinib: Stage 1 Results at 24 Weeks

[0209]Demographic data for the 27 patients enrolled in the four treatment arms of the study described above in Example 1 is summarized in Table 2 below. The patients enrolled in the study included those with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (Post-PV MF) or post essential thrombocythemia myelofibrosis (Post-ET MF), classified as Intermediate-1, Intermediate-2, or high risk MF according to the Dynamic International Prognostic Scoring System (DIPSS). 15 of the 27 patients had been treated with a JAK inhibitor prior to the current study. Of the 27 patients who enrolled in the study and started treatment, 18 patients completed 24 weeks and evaluation was ongoing for 3 patients who had not reached the 24-week mark. Patient cohorts are as described above.

TABLE 2PRM-151 QWPRM-151 Q4WPRM-151 QW +PRM-151 Q4W + Demographic Info(Cohort 2)(Cohort 1)RUX (C...

example 3

Representative Individual Patient Data

[0217]A representative example of response data from one responsive patient is shown here. The hemoglobin, platelet, MPN-SAF TSS, and spleen response trends to treatment with rhSAP over the course of 24 weeks for patient 101-005 are shown in FIGS. 3A-D. Patient 101-005 was treated with SAP every 4 weeks (Cohort 1). Patient characteristics are summarized in Table 4 below.

TABLE 4DIPSS Years since# priorTyperisk groupinitial diagnosistherapiesPMFIntermediate-273

[0218]As seen in FIG. 3, patient 101-005 showed an improvement in hemoglobin and platelet levels, a reduction in MPN-SAF TSS and a reduction in spleen size over the course of treatment. In addition, patient 101-005 showed a decrease in bone marrow fibrosis from Grade 2 to Grade 0 at 12 weeks (FIG. 4).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to and the benefit of U.S. provisional patent application Ser. Nos. 61 / 888,269 filed on Oct. 8, 2013, 61 / 992,807 filed on May 13, 2014, 62 / 004,828 filed on May 29, 2014, and 62 / 004,836 filed on May 29, 2014, the disclosures of which are incorporated herein by reference in their entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 6, 2014, is named 104112-0022-WO1_SL.txt and is 7,604 bytes in size.BACKGROUND OF THE INVENTION[0003]Certain cancers and proliferative conditions are characterized by the growth of dense connective tissue within and around a neoplasm, replacing normal tissue. Such fibrotic cancers are difficult to treat because chemotherapeutic agents often cannot penetrate the dense fibrotic stroma surrounding the cancer ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K31/519
CPCA61K38/1716A61K45/06A61K38/1709A61K31/519A61K2300/00A61P19/08A61P35/00A61P35/02A61K31/7088A61K39/395
Inventor BRUHN, SUZANNETREHU, ELIZABETHLUPHER, MARK
Owner PROMEDIOR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com